Skip to Main Content
Imvax
  • About Us
    • Overview
    • Leadership Team
    • Board of Directors
    • Scientific Advisors
  • Our Science
    • Overview
    • Our GoldspireTM Platform
    • Advantages
    • Publications
  • Pipeline
    • Overview
    • Imvax Programs
      • IGV-001
      • IHC-001
      • IUC-001
      • ICC-001
      • IEC-001
      • IOC-001
    • Clinical Trials
  • News & Events
  • Patients & Families
    • Glioblastoma
    • Clinical Trials
    • Resources
    • Contact Us
  • Culture & Careers
    • Our People
    • Benefits
    • Career Opportunities

News & Partnering

Press releases

Year
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
April 17, 2023

Imvax Presents New Data at AACR 2023 Supporting the Mechanism of Action of its Lead Program, IGV-001, for Glioblastoma

March 27, 2023

Imvax Announces First Patient Dosed in Phase 2b Trial of IGV-001 for Glioblastoma

November 10, 2022

Imvax Presents Preclinical Data at SITC 2022 Supporting Mechanism of Action and Anti-tumor Activity of its Immunotherapy Platform Across Multiple Tumor Types

October 6, 2022

Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 SITC Meeting

In the News

Year
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
April 21, 2023 | Local 12 - WKRC

University of Cincinnati researchers helping develop ‘vaccine’ to fight aggressive cancer

March 30, 2023 | BioBuzz

Imvax Charges Ahead with Phase IIb Glioblastoma Trial

Upcoming Events

None at this time, stay tuned!

601 Walnut Street, Suite 440W, Philadelphia, PA 19106
267-900-4110
contact@imvax.com

  • Careers at Imvax
  • Privacy Policy
  • Terms of Use
  • LinkedIn
  • Twitter
© Copyright 2023 Imvax®, Inc. All rights reserved.